COMUNICADO: KLOX System Poised to Become Leading Acne Treatment (y 2)

Actualizado 15/07/2013 10:23:49 CET

Currently, KLOX is also developing the WH-1 BioPhotonic System, an innovative light-based treatment for the multi-billion dollar advanced wound care market. The WH-1 BioPhotonic System is being investigated to treat pressure ulcers, diabetic and venous leg ulcers with the goal to significantly accelerate healing in an optimal environment. Four Investigational Testing Authorization trials are currently advancing in Canada to evaluate the safety and preliminary efficacy of the WH-1 BioPhotonic System in the treatment of Stage II pressure ulcers, venous leg and ulcers.

Forward Looking Statements

Certain statements contained in this presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward-looking statements include those regarding cosmetics and medical devices and medical applications and clinical trials and the status and related results thereto, as well those regarding continuing and further development efforts. Such statements, based as they are on the current analysis and expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond KLOX Technologies Inc.'s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the medical, cosmetics and/or consumer goods industries, changes in the regulatory environment in the jurisdictions in which KLOX Technologies Inc. does business, financial and commercial markets volatility, fluctuations in costs, and changes to the competitive environment, as well as other risks. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. In the case of forward-looking statements regarding investigational product candidates and continuing and further development efforts, specific risks which could cause actual results to differ materially from KLOX Technologies Inc.'s current analysis and expectations include: failure to demonstrate the safety, tolerability and efficacy of our products, final and quality controlled verification of data and the related analyses, and the expense and uncertainty of obtaining regulatory approval.


INFORMATION:
Business, Consumer and Marketing Media:
Roch Landriault
NATIONAL Public Relations
+1(514)843-2345

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación

Esta web utiliza cookies propias y de terceros para analizar su navegación y ofrecerle un servicio más personalizado y publicidad acorde a sus intereses. Continuar navegando implica la aceptación de nuestra política de cookies -
Uso de cookies